Abstract
NF-κB plays an important role in cancer initiation and progression. CD44, a cell surface glycoprotein, is involved in many cellular processes including cell adhesion, migration and proliferation. However, whether and how the two molecules interact in breast cancer is not clear. In recent years, the up-regulation of CD44 has served as a marker for tumor initiating cells in breast cancer and other cancer types. Despite the important role of CD44 in cellular processes and cancer, the mechanism underlying CD44 up-regulation in cancers remains poorly understood. Previously, we have identified a novel cis-element, CR1, located upstream of the CD44 promoter. We demonstrated that NF-κB and AP-1 are key trans-acting factors that interact with CR1. Here, we further analyzed the role of NF-κB in regulating CD44 expression in triple negative breast cancer cells, MDA-MB-231 and SUM159. Inhibition of NF-κB by Bay-11-7082 resulted in a reduction in CD44 expression. CD44 repression via NF-κB inhibition consequently decreased proliferation and invasiveness of breast cancer cells. These findings provide not only new insight into the molecular mechanism underlying CD44 regulation but also potential therapeutic targets that may help eliminate chemo- and radiation-resistant cancer cells.
Highlights
Breast cancers are known to contain a heterogeneous population of cells
We showed that CR1 activity is modulated by the transcription factors NF-kB and AP-1 via electrophoretic mobility shift assays (EMSA), EMSA supershift, and chromatin immunoprecipitation (ChIP) assays
Bay-11-7082 has previously been shown to inhibit NF-kB binding to DNA by preventing phosphorylation of the Inhibitor of kB (IkB) by the IkB Kinase (IKK) [20,21,22,23]
Summary
There is a small subset of cells with a unique cell surface marker signature (e.g., up-regulation of CD44 and down-regulation of CD24) as well as characteristics similar to stem cells such as the ability to self-renew, differentiate and they have been shown to be chemo-and radiation resistant [1,2,3,4,5,6] These cells, known as cancer stem-like cells or tumor initiating cells (TICs), have been observed in other cancers including prostate, pancreatic, brain and leukemia [7,8,9], making CD44 an important target for cancer therapies. CD44 repression by miR-34a inhibits prostate TICs and metastasis [12]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.